Joseph Stringer
Stock Analyst at Needham
(4.18)
# 466
Out of 4,974 analysts
310
Total ratings
45.65%
Success rate
16.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $55 → $70 | $59.35 | +17.94% | 23 | Sep 2, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $54 → $74 | $64.85 | +14.11% | 14 | Aug 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $453.54 | +5.39% | 23 | Jul 31, 2025 | |
| GILD Gilead Sciences | Upgrades: Buy | $133 | $112.77 | +17.94% | 7 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $72 → $95 | $104.45 | -9.05% | 25 | Jul 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $19.63 | +12.07% | 23 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $12.00 | +133.33% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.15 | +171.84% | 18 | May 22, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.15 | +411.63% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $28.65 | +1.22% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $396.93 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $48.47 | +23.79% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $32.15 | +179.94% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.07 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.63 | +513.50% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $24.28 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $25.50 | +45.10% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $14.05 | +28.11% | 2 | Aug 24, 2021 |
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $55 → $70
Current: $59.35
Upside: +17.94%
Cidara Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $54 → $74
Current: $64.85
Upside: +14.11%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $453.54
Upside: +5.39%
Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $112.77
Upside: +17.94%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72 → $95
Current: $104.45
Upside: -9.05%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $19.63
Upside: +12.07%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $12.00
Upside: +133.33%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.15
Upside: +171.84%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.15
Upside: +411.63%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $28.65
Upside: +1.22%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $396.93
Upside: -
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $48.47
Upside: +23.79%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $32.15
Upside: +179.94%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.07
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.63
Upside: +513.50%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $24.28
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $25.50
Upside: +45.10%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $14.05
Upside: +28.11%